Compare ALEMBIC PHARMA with Aventis Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs SANOFI INDIA - Comparison Results

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA SANOFI INDIA ALEMBIC PHARMA/
SANOFI INDIA
 
P/E (TTM) x 16.3 35.5 46.0% View Chart
P/BV x 3.8 6.2 60.4% View Chart
Dividend Yield % 1.0 1.4 72.4%  

Financials

 ALEMBIC PHARMA   SANOFI INDIA
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-19
SANOFI INDIA
Dec-18
ALEMBIC PHARMA/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs6646,840 9.7%   
Low Rs4124,630 8.9%   
Sales per share (Unadj.) Rs208.71,203.1 17.3%  
Earnings per share (Unadj.) Rs31.0165.3 18.8%  
Cash flow per share (Unadj.) Rs37.1209.9 17.7%  
Dividends per share (Unadj.) Rs5.5084.00 6.5%  
Dividend yield (eoy) %1.01.5 69.8%  
Book value per share (Unadj.) Rs144.2963.6 15.0%  
Shares outstanding (eoy) m188.5223.03 818.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.64.8 54.1%   
Avg P/E ratio x17.434.7 50.0%  
P/CF ratio (eoy) x14.527.3 53.1%  
Price / Book Value ratio x3.76.0 62.7%  
Dividend payout %17.750.8 34.9%   
Avg Mkt Cap Rs m101,461132,078 76.8%   
No. of employees `000NA3.3 0.0%   
Total wages/salary Rs m7,4674,068 183.6%   
Avg. sales/employee Rs ThNM8,393.8-  
Avg. wages/employee Rs ThNM1,232.4-  
Avg. net profit/employee Rs ThNM1,153.0-  
INCOME DATA
Net Sales Rs m39,34727,708 142.0%  
Other income Rs m94897 10.5%   
Total revenues Rs m39,44128,605 137.9%   
Gross profit Rs m8,7366,235 140.1%  
Depreciation Rs m1,1521,027 112.2%   
Interest Rs m1847 2,630.0%   
Profit before tax Rs m7,4936,098 122.9%   
Minority Interest Rs m110-   
Prior Period Items Rs m-930-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,5682,292 68.4%   
Profit after tax Rs m5,8443,806 153.5%  
Gross profit margin %22.222.5 98.7%  
Effective tax rate %20.937.6 55.7%   
Net profit margin %14.913.7 108.1%  
BALANCE SHEET DATA
Current assets Rs m19,57715,922 123.0%   
Current liabilities Rs m14,8966,235 238.9%   
Net working cap to sales %11.935.0 34.0%  
Current ratio x1.32.6 51.5%  
Inventory Days Days9064 141.0%  
Debtors Days Days4521 217.3%  
Net fixed assets Rs m27,0977,539 359.4%   
Share capital Rs m377230 163.9%   
"Free" reserves Rs m26,81121,962 122.1%   
Net worth Rs m27,18822,192 122.5%   
Long term debt Rs m4,9930-   
Total assets Rs m47,77829,839 160.1%  
Interest coverage x41.7872.1 4.8%   
Debt to equity ratio x0.20-  
Sales to assets ratio x0.80.9 88.7%   
Return on assets %12.612.8 98.7%  
Return on equity %21.517.2 125.3%  
Return on capital %23.627.5 85.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m19,4537,587 256.4%   
Fx outflow Rs m6,0657,145 84.9%   
Net fx Rs m13,388442 3,028.9%   
CASH FLOW
From Operations Rs m8,1203,739 217.2%  
From Investments Rs m-7,556-731 1,033.7%  
From Financial Activity Rs m590-1,972 -29.9%  
Net Cashflow Rs m1,1531,036 111.3%  

Share Holding

Indian Promoters % 74.1 0.0 -  
Foreign collaborators % 0.0 60.4 -  
Indian inst/Mut Fund % 2.9 14.4 20.1%  
FIIs % 9.1 14.6 62.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 10.5 132.4%  
Shareholders   49,328 15,184 324.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   STERLING BIOTECH  PFIZER  DR. DATSONS LABS  ORCHID PHARMA LTD  NOVARTIS  

Compare ALEMBIC PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 246 Points Higher; Capital Goods and Power Stocks Witness Buying(Closing)

Extending gains to the sixth day, Indian share markets traded on a positive note most of the day and ended higher.

Related Views on News

ALEMBIC PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 36.4% (Quarterly Result Update)

Aug 21, 2019 | Updated on Aug 21, 2019

For the quarter ended June 2019, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 36.4% YoY). Sales on the other hand came in at Rs 9 bn (up 10.0% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

SANOFI INDIA Announces Quarterly Results (1QFY20); Net Profit Down 2.2% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, SANOFI INDIA has posted a net profit of Rs 974 m (down 2.2% YoY). Sales on the other hand came in at Rs 7 bn (up 9.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

ALEMBIC PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 13, 2019 | Updated on Jun 13, 2019

Here's an analysis of the annual report of ALEMBIC PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.

ALEMBIC PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 28.9% (Quarterly Result Update)

May 9, 2019 | Updated on May 9, 2019

For the quarter ended March 2019, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 28.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.6% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

SANOFI INDIA Announces Quarterly Results (4QFY19); Net Profit Up 12.6% (Quarterly Result Update)

May 8, 2019 | Updated on May 8, 2019

For the quarter ended March 2019, SANOFI INDIA has posted a net profit of Rs 929 m (up 12.6% YoY). Sales on the other hand came in at Rs 7 bn (up 16.1% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Oct 18, 2019 03:37 PM

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA 8-QTR ANALYSIS

COMPARE ALEMBIC PHARMA WITH

MARKET STATS